Skip to main content
Torch

Dr David Allsup

Senior Lecturer in Haematology and Honorary Consultant

Faculty and Department

  • Faculty of Health Sciences
  • Hull York Medical School

Qualifications

  • BSc (University of Leicester)
  • PhD (University of Liverpool)
  • BSc (University of Leicester)

Summary

Dr David Allsup is a Senior Lecturer in Haematology with an Honorary NHS appointment with Hull and East Yorkshire Hospitals NHS Trust, based in the Queens Centre for Oncology and Haematology at Castle Hill Hospital. He is the local haemophilia director and has additional clinical interests in inherited and acquired platelet disorders. He is also the local lead for chronic lymphocytic leukaemia (CLL), in which he has a longstanding research interest.

Dr Allsup is a keen educator and supporter of the next generation of scientists and clinicians. His teaching roles include:-

Undergraduate medical student teaching in phase II.

Haematology postgraduate teaching.

Educational and clinical supervisor to medical and haematology trainees.

External examiner for PhDs.

Recent outputs

View more outputs

Journal Article

Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL

Antic, D., Milic, N., Chatzikonstantinou, T., Scarfò, L., Otasevic, V., Rajovic, N., …Stamatopoulos, K. (2022). Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL. Journal of Hematology & Oncology, 15(1), Article 116. https://doi.org/10.1186/s13045-022-01333-0

PRO: Biomarker surveillance for invasive fungal infections without antifungal prophylaxis could safely reduce antifungal use in acute leukaemia

Taynton, T., Barlow, G., & Allsup, D. (2022). PRO: Biomarker surveillance for invasive fungal infections without antifungal prophylaxis could safely reduce antifungal use in acute leukaemia. JAC-Antimicrobial Resistance, 4(4), Article dlac074. https://doi.org/10.1093/jacamr/dlac074

Adherence to ibrutinib remains an unmet clinical need in chronic lymphocytic leukemia

Molica, S., Allsup, D. J., & Polliack, A. (2022). Adherence to ibrutinib remains an unmet clinical need in chronic lymphocytic leukemia. Leukemia & Lymphoma, https://doi.org/10.1080/10428194.2022.2087072

Time-limited, chemotherapy-free treatment comes of age in chronic lymphocytic leukaemia

Molica, S., & Allsup, D. J. (2022). Time-limited, chemotherapy-free treatment comes of age in chronic lymphocytic leukaemia. The lancet oncology, 23(6), 699-701. https://doi.org/10.1016/S1470-2045%2822%2900266-2

Immunomodulation mediated by polyclonal IgG replacement in patients with chronic lymphocytic leukemia may be important in infection prevention

Khan, S., Molica, S., & Allsup, D. (2022). Immunomodulation mediated by polyclonal IgG replacement in patients with chronic lymphocytic leukemia may be important in infection prevention. Hematological Oncology, https://doi.org/10.1002/hon.3011

Research interests

His research interests include:-

Platelet disorders.

The biology of chronic lymphocytic leukaemia.

Novel therapeutic approaches for haematological malignancies.

Clinical trials.

Patient pathways.

Lead investigator

Project

Funder

Grant

Started

Status

Project

CLL Research

Funder

Hull University Teaching Hospitals NHS Trust

Grant

£35,000.00

Started

26 January 2015

Status

Ongoing

Project

The Biomarker Driven Antifungal Stewardship in AML: The BioDriveAFS Trial

Funder

NIHR National Institute for Health Research

Grant

£96,343.00

Started

1 September 2021

Status

Ongoing

Project

STATIC: A Randomised Phase III Trial Comparing Continuous with Intermittent Treatment Strategies in Chronic Lymphocytic Leukaemia (CLL)

Funder

NIHR National Institute for Health Research

Grant

£29,602.00

Started

1 January 2021

Status

Ongoing

Project

B-More: A 24-month prospective, non-interventional, international, multicentre study to describe the real-world effectiveness and usage of Alprolix in patients with haemophilia B in selected European and Middle Eastern countries

Funder

Hull University Teaching Hospitals NHS Trust

Grant

£2,288.00

Started

1 September 2019

Status

Complete

Co-investigator

Project

Funder

Grant

Started

Status

Project

LIPS: A prospective registry-based cohort study to monitor the diagnosis and management of acute leukaemia in pregnancy

Funder

Blood Cancer UK

Grant

£71,112.00

Started

1 June 2018

Status

Complete

Postgraduate supervision

Inherited and acquired platelet disorders.

Chronic lymphocytic leukaemia.

Novel treatments for leukaemia.

Clinical trials.

Patient experience of cancer.

Clinical role

Honorary Consultant

2018 - 2025

Honorary Consultant

Committee/Steering group role

Member of Trial Managment Group for STATIC clinical trial

2022 - 2030

Member of United Kingdom Haemophilia Directors Executive Commitee

2021 - 2025

Member of Trial Management Group for LIPS

2018 - 2022

Co-investigator, and member of trial management group, of a registry study of acute leukaemia and pregnancy.

Member of Trial Management Group FLAIR clinical trial

2013 - 2025

Member of Trial Management Group FLAIR clinical trial

NCRI CLL clinical studies subgroup member

2010 - 2025

NCRI CLL clinical studies subgroup member

Conference presentation

The Integration of Efficacy and Safety Outcomes Identifies the Net Clinical Benefit of Targeted Agents in Upfront Therapy of Chronic Lymphocytic Leukemia: Results of Network Meta-Analysis

2022 - 2022

Conference presentation American Society of Haematology 2022

Combination of Ibrutinib Plus Venetoclax with MRD-Driven Duration of Treatment Results in a Higher Rate of MRD Negativity in IGHV Unmutated Than Mutated CLL: Updated Interim Analysis of FLAIR Study

2022 - 2022

Conference presentation American Society of Haematology, 2022

Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study

2022 - 2022

Conference presentation American Society of Haematology 2022

P673: DEPLETION AND RECOVERY OF NORMAL B-CELLS DURING AND AFTER TREATMENT WITH CHEMOIMMUNOTHERAPY, IBRUTINIB OR VENETOCLAX

2022 - 2022

Conference presentation, European Haematology Association Congress 2022.

THE COMBINATION OF IBRUTINIB PLUS VENETOCLAX RESULTS IN A HIGH RATE OF MRD NEGATIVITY IN PREVIOUSLY UNTREATED CLL: THE RESULTS OF THE PLANNED INTERIM ANALYSIS OF THE PHASE III NCRI FLAIR TRIAL

2022 - 2022

Conference presentation European Haematology Association Congress

Biomarker Driven Antifungal Stewardship in Acute Leukaemia (BioDriveAFS)—a multicentre randomized controlled trial to assess clinical and cost effectiveness

2022 - 2022

Conference presentation, BSAC meeting, London 2022.

Sudden or Cardiac Deaths on Ibrutinib-Based Therapy were associated with a prior History of Hypertension or Cardiac Disease and the use of ACE-Inhibitors at Study Entry: Analysis from the Phase III NCRI FLAIR Trial

2022 - 2022

Conference presentation British Society for Haematology, 2022

The impact of bacterial superantigens on T cell exhaustion in chronic lymphocytic leukemia (CLL) patients

2021 - 2021

Poster presentation at British Society for Immunology

Ten-year follow-up of 415 CLL patients treated with fludarabine cyclophosphamide-based chemoimmunotherapy in the frontline ARCTIC and ADMIRE trials, a comprehensive assessment of prognostic factors.

2021 - 2021

Poster presentation at European Haematology Association

B-MORE, Baseline Analysis from a 24-month Prospective, Non-interventional, Multicentre Study on Real-world Effectiveness and Usage of Recombinant Factor IX Fc (rFIXFc) in Haemophilia B

2021 - 2021

Poster presentation at International Society for Thrombosis and Haemostasis

Ibrutinib Plus Rituximab Is Superior to FCR in Previously Untreated CLL: Results of the Phase III NCRI FLAIR Trial

2021 - 2021

Presentation at American Society of Haematology

Sudden or Cardiac Deaths on Ibrutinib-Based Therapy Were Associated with a Prior History of Hypertension or Cardiac Disease and the Use of ACE-Inhibitors at Study Entry: Analysis from the Phase III NCRI FLAIR Trial

2021 - 2021

Presentation at American Society of Haematology

A single centre study to assess delivery of vaccination advice to patients with chronic lymphocytic leukaemia

2021 - 2021

British Society of Haematology Meeting, virtual

Splenectomy in immune thrombocytopenia: do changing treatment patterns for ITP affect outcome? Data from the UK ITP registry

2020 - 2020

Co-author on above presentation at BSH 2020

Btk inhibitors Ibrutinib and Acalabrutinib impair Fc?RIIA-mediated responses of healthy donor platelets and Chronic Lymphocytic Leukaemia platelets to bacteria.

2020 - 2020

Co-author on above poster presentation at BSH 2020.

Telomere Length and CD49d Cooperate with IGHV Gene Status As Predictors of Long-Term Progression-Free Survival in CLL Patients Treated with FCR-Based Regimens

2020 - 2020

Poster presentation American Society for Haematology Andrea GS Pepper, PhD1*, Antonella Zucchetto, PhD2*, Kevin Norris, PhD3*, Erika Tissino, PhD4*, Jerry Polesel5*, Zarni Soe6*, David Allsup7*, Anna Hockaday8*, Pei Loo Ow9*, Peter Hillmen, MBChB, PhD10*, Andrew Rawstron, PhD11*, Daniel Catovsky, MD, FRCP12, Riccardo Bomben, PhD2*, Duncan M Baird, PhD13*, Christopher Fegan14*, Valter Gattei, MD15 and Chris Pepper, BSc, PhD16

Bruton's Tyrosine Kinase Inhibitors Impair Fc?riia-Mediated Responses of Healthy Donor Platelets and Chronic Lymphocytic Leukaemia Derived Platelets to Bacteria

2020 - 2020

1748 Bruton's Tyrosine Kinase Inhibitors Impair Fc?riia-Mediated Responses of Healthy Donor Platelets and Chronic Lymphocytic Leukaemia Derived Platelets to Bacteria Program: Oral and Poster Abstracts Session: 203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections: Poster II Hematology Disease Topics & Pathways: Leukemia, Diseases, CLL, Therapies, Biological Processes, Lymphoid Malignancies, Clinically relevant, immune mechanism, pathways Sunday, December 6, 2020, 7:00 AM-3:30 PM Leigh Naylor-Adamson1*, Zoe Booth2*, Simon Hart3*, Russell Patmore4, Sujoy Khan5*, David Allsup6* and Monica Arman6* 1Centre for Atherothrombosis and Metabolic Disease, Hull York Medical School, Owston Ferry, ENG, United Kingdom 2Centre for Atherothrombosis and Metabolic Disease, University of Hull, Hull, ENG, United Kingdom 3Respiratory Research Group, Hull York Medical School, Hull, ENG, United Kingdom 4Department of Haematology, Hull and East Yorkshire Hospitals NHS Trust, Hull, ENG, United Kingdom 5Department of Immunology & Allergy, Hull and East Yorkshire Hospitals NHS Trust, Hull, ENG, United Kingdom 6Centre for Atherothrombosis and Metabolic Disease, Hull York Medical School, Hull, ENG, United Kingdom

Btk Inhibitor Ibrutinib Impairs Fc?RIIa-Mediated Responses of Platelets from Healthy Donors and Chronic Lymphocytic Leukaemia Patients to Bacteria

2020 - 2020

Authors: Leigh Naylor-Adamson1, Zoe Booth1, Simon P. Hart3, David J Allsup1,4, and Mònica Arman1 Affiliations: 1Centre for Atherothrombosis and Metabolic Disease, Hull York Medical School, University of Hull; 2Respiratory Research Group, Hull York Medical School, University of Hull; 3Department of Haematology, Queens Centre for Oncology and Haematology, Castle Hill Hospital, Hull and East Yorkshire Hospitals NHS Trust. Poster British Society Haematology Meeting 2020

Multicenter Genome Wide Association Study Identifies Constitutional Risk Alleles for Progressive Chronic Lymphocytic Leukemia

2019 - 2019

David Allsup, Wei-Yu Lin, Sarah Fordham, Nicola Sunter, Claire Elstob, Thahira Rahman, Elaine Willmore, Colin Shepherd, Gordon Strathdee, Timothy Barrow, Tryfonia Mainou-Fowler, Rachel Piddock, Helen Marr, Jonathan Wallis, Scott Marshall, Andrew Pettitt, Christopher Pepper, Christopher Fegan, Francesco Forconi, Martin JS Dyer, Sandrine Jayne, April Sellors, Anna Schuh, Pauline Robbe David Oscier, Richard S. Houlston, James Bailey, Syed Rais, Alison Bentley, Lynn Cawkwell, Peter Hillmen, Guy Pratt , James Allan. Conference presentation, American Society for Haematology, Orlando, December 2019.

SPLENECTOMY IN IMMUNE THROMBOCYTOPENIA: DO CHANGING TREATMENT PATTERNS FOR ITP AFFECT OUTCOMES? DATA FROM THE UK ITP REGISTRY

2019 - 2019

European Haematology Association Annual Congress

COSMIC, a phase II randomised study investigating the efficacy of standard or high-dose ofatumumab in combination with chemotherapy in patients with relapsed chronic lymphocytic leukaemia

2017 - 2017

Poster presentation , International Workshop Chronic Lymphocytic Leukaemia New York

Training in safe administration of intrathecal chemotherapy – is in situ simulation the answer?: A pilot study

2015 - 2015

BMJ Simulation & Technology Enhanced Learning

New UKHCDO von Willebrand disease guidelines allow re-classification of a large proportion of adult patients and can result in de-diagnosis of patients without haemorrhagic consequences

2015 - 2015

Poster presentation British Society for Haematology Meeting

External examiner role

External Phd examiner.

2004 - 2019

Dr Allsup has acted as external examiner in six PhD vivas.

Journal peer reviewer

Peer reviewer

2018 - 2023

Peer reviewer for multiple journals including American Journal of Haematology, British Journal of Haematology, Cellular Signalling, Expert Opinion Therapeutic Targets, Leukaemia Research, European Journal of Haematology.

Peer reviewer for funding bodies including MRC, Wellcome, NW Cancer, Roy Castle , Leukaemia UK, Great Ormond Street

2018 - 2023

Membership/Fellowship of professional body

Fellow Higher Education Academy

2019 - 2025

United Kingdom Chronic Lymphocytic Leukaemia Forum

2010 - 2025

UKHCDO

2005 - 2025

Member of United Kingdom Haemophilia Centre Directors Organisation.

FRCPath

2004 - 2025

Fellow Royal College of Pathologist

BSH

2000 - 2025

Member of British Society for Hematology

MRCP

1996 - 1996

MRCP

Top